Characterization of Glioblastoma Cells Response to Regorafenib

Characterization of Glioblastoma Cells Response to Regorafenib

Glioblastoma (GBM), the most malignant primary brain tumor in adults. Although not frequent, it has a relevant social impact because the peak incidence coincides with the age of professional maturity. A number of novel treatments have been proposed, yet clinical trials have been disappointing. Recen...

Full description

Bibliographic Details
Main Authors: Maria Patrizia Mongiardi, Mariachiara Buccarelli, Alessia Formato, Elisa Orecchini, Maria Salbini, Valentina Ricci, Tiziana Orsini, Sabrina Putti, Silvia Chiesa, Lucia Ricci-Vitiani, Quintino Giorgio D’Alessandris, Roberto Pallini, Andrea Levi, Maria Laura Falchetti
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
glioblastoma
therapy
regorafenib
glioma stem cells (GSCs)
epithelial to mesenchymal transition (EMT)
Online Access:https://www.mdpi.com/2072-6694/14/24/6193

Internet

https://www.mdpi.com/2072-6694/14/24/6193

Similar Items